Argent Biopharma Limited Annual Report for the year ended 30 June 2024
September 30 2024 - 3:34AM
RNS Regulatory News
RNS Number : 2278G
Argent Biopharma Limited
30 September 2024
30
September 2024
Argent BioPharma
Ltd.
(Argent BioPharma or the Company)
Annual Report for the year
ended 30 June 2024
and ASX Corporate Governance
Statement
Argent BioPharma, an innovative
multidisciplinary drug discovery company within the
biopharmaceutical sector is pleased to provide the following
documents in respect of the financial year ended 30 June
2024:
·
Annual Financial
Report (Audited)
A copy of the Company's Annual
Financial Report for the year ended 30 June 2024 can be found at
the following URL:
https://www.investi.com.au/api/announcements/rgt/f19a9293-4b8.pdf
·
ASX Appendix 4G
"Key disclosures - Corporate Governance Council Principles and
Recommendations" and Argent BioPharma's Corporate Governance
Statement
A copy of the Company's ASX Appendix
4G - Corporate Governance Disclosures & Corporate Governance
Statement can be found at the following URL:
https://www.investi.com.au/api/announcements/rgt/81d037ff-a07.pdf
-Ends-
Authorised for release by the board of directors, for further
information please contact:
About Argent
BioPharma
Argent BioPharma Limited (the
Company) (ASX: RGT; LSE:
RGT; OTCQB: RGTLF) an innovative multidisciplinary drug development
Company within the biopharmaceutical sector. The Company
focuses on multidisciplinary methods with Nanotechnology,
developing multi-target therapies for comprehensive disease
management, especially concerning the Central nervous system
(CNS) and Immunology
treatments.
Follow us through our social media
channels:
LinkedIn: Argent
BioPharma
Twitter: @ArgentBioPharma
Facebook: Argent BioPharma
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact
rns@lseg.com or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our
Privacy
Policy.
END
ACSVBLBXZKLXBBF
Argent Biopharma (LSE:RGT)
Historical Stock Chart
From Oct 2024 to Nov 2024
Argent Biopharma (LSE:RGT)
Historical Stock Chart
From Nov 2023 to Nov 2024
